Abu Dhabi’s Technology Innovation Institute Unveils the Arab World’s First Electromagnetic Compatibility Labs
3.5.2021 11:01:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Centre (DERC) has unveiled its Electromagnetic Compatibility (EMC) laboratories in Abu Dhabi, housed in a first of its kind facility in the Arab world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005336/en/
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre, Technology Innovation Institute (Photo: AETOSWire)
The facility is composed of three laboratories - an EMC semi-anechoic chamber, a pulsed power laboratory, and a low-noise emanation laboratory.
The DERC facility enables key technologies to be evaluated against electromagnetic compatibility and interference by reproducing man-made and natural electromagnetic hazards in the pulsed power and semi-anechoic chambers. The direct connection between the two chambers enables a diversity of experiments involving 100’s of kV nanosecond pulses and multi-megawatt microwaves systems. The laboratories have been designed to host different categories of equipment such as connected objects of the Internet of Things, drones and autonomous cars, telecommunications equipment, medical devices, automotive equipment, IT equipment and is fully automated for tests and measurements. A unique low-noise emanation lab has been built on DERC specifications that allow for the study of very low noises emitted by electronic systems.
Electromagnetic compatibility, or EMC, allows electronic devices that are near each other to operate without mutual interference, known as Electromagnetic Interference, EMI. The operation of electronic circuits can be compromised as they can radiate or pick up unwanted interference. Highlighting the significance of EMC is the fact that the number of devices connected wirelessly is constantly on the rise.
H.E. Faisal Al Bannai, Secretary General of ATRC, said: “The launch of these labs, which are the first and the largest in the Arab world, is aligned with the Ministry of Industry and Advanced Technology’s (MoIAT) ’Operation 300bn’ which aims to advance the industrial sector, a mandate which we fully support at ATRC as the organisation defining Abu Dhabi’s and the UAE’s research strategy across academia and industry. ATRC is investing in cutting-edge laboratories that will support in-country R&D and local industry, and encourage innovation in line with international standards. By opening these unique laboratories, non-existent before in the Arab region, we want to support innovators from prototype to a qualified system.”
DERC is pioneering research in high energy physics, and the effects of high intensity fields on different materials, systems, and environments. The Centre is committed to using its cutting-edge position in science to search for practical solutions that benefit society in diverse areas. In EMC/EMI, DERC’s research domains include modelling of the EM environment produced by human-made sources; design, production, and evaluation of antennas; innovative materials for EM shielding applications; modelling of the electro-thermal response of industrial systems; and lightning protection.
Dr. Chaouki Kasmi, Chief Researcher at Directed Energy Research Centre, said: “At DERC we support research on a wide range of topics in EMC and EMI on behalf of governments and enterprises to help create and maintain advanced electronic systems. We are excited to announce the launch of the EMC labs in Abu Dhabi. They will help in pre-qualification of electronics against Electromagnetic Compatibility and Interference Standards as well as hardening of critical infrastructures to operate safely in harsh environments.”
“Many electromagnetic compatibility standards have been introduced over the years, making EMC a key part of the electronics design process,” Dr. Kasmi said. “With standards now implemented and enforced globally, manufacturers have to ensure that new electronic products meet the relevant EMC standards.”
For more information about Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005336/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom